VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced and/or metastatic solid tumor or lymphoma for which no curative or standard effective therapy exists
• Measurable or evaluable metastatic disease
• No other hematologic malignancy
• No large pleural, pericardial, or peritoneal effusions
• No requirement for immediate palliative treatment, including surgery
• No symptomatic brain metastases or metastases with substantial edema
• * Asymptomatic brain metastases or primary CNS disease allowed if neurologic deficits are stable
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-1
• Life expectancy:
• At least 3 months
• Hematopoietic:
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hematocrit at least 30% (transfusion allowed)
• No active uncontrolled bleeding
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)
• Alkaline phosphatase no greater than 1.5 times ULN (3 times ULN if liver or bone metastases present)
• PT and aPTT no greater than 1.5 times ULN
• Albumin at least 2.5 g/dL
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• Ejection fraction at least 45%
• No active heart disease
• No myocardial infarction within the past 3 months
• No symptomatic coronary artery disease
• No arrhythmias requiring medication
• No uncontrolled congestive heart failure
• Pulmonary:
• DLCO and FEV\_1 at least 60% of predicted
• No dyspnea with minimal to moderate exertion
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• HIV negative
• No active infection
• Persistent stable chronic toxic effects from prior therapy allowed if no greater than grade 1
• No bleeding diathesis (e.g., active peptic ulcer disease)
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 3 weeks since prior biologic agents and recovered
• At least 6 months since prior high-dose chemotherapy regimen with stem cell support
• Chemotherapy:
• See Biologic therapy
• At least 3 weeks since prior cytotoxic agents (6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy:
• At least 2 weeks since prior hormonal therapy and recovered
• Radiotherapy:
• At least 3 weeks since prior radiotherapy and recovered
• Surgery:
• See Disease Characteristics
• At least 2 weeks since prior surgery and recovered
• Other:
• No other concurrent standard therapy for cancer
• No other concurrent investigational agents
• No concurrent disulfiram (Antabuse)